Patients with abnormal bleeding and endometrial proliferative and Hayprplastyk with irregular glands. Endometrial glandular hyperplasia
Conditions
Interventions
Intervention 1: In the third group with cervical cancer:Drug letrozole (made in Iran, Iran Hormone) 2.5 mg BID and 500 mg BID Metformin is prescribed for three months. Intervention 2: Group II endomet
Treatment - Drugs
In the third group with cervical cancer:Drug letrozole (made in Iran, Iran Hormone) 2.5 mg BID and 500 mg BID Metformin is prescribed for three months.
Group II endometrial proliferative effect:Drug letrozole (made in Iran, Iran Hormone) 2.5 mg BID and 500 mg BID Metformin is prescribed for three months.
The first group with abnormal uterine bleeding: Drug letrozole (made in Iran, Iran Hormone) 2.5 mg BID and 500 mg BID Metformin is prescribed for three months.
Sponsors
Vice chancellor for Research,Tabriz University Of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with abnormal uterine bleeding and havingdisordered proliferative or hyperplastic endometrium and uterine cancer;Consent to participate Exclusion criteria:People who are allergic to metformin and letrozole, severe impairment of hepatic function; Uncontrolled high blood pressure; Thromboembolism
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histologic types of endometrial. Timepoint: Three months after the first dose. Method of measurement: Microscopic examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Elaheh Ouladsahebmadarek
Tabriz University Of Medical Sciences
Outcome results
None listed